Formulary assessment – Melatonin (Ceyesto) 1mg/ml oral solution

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Monthly Horizon Scanning Report – February 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Shared care protocol – hydroxycarbamide in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Shared care protocol – ciclosporin (oral) for adults (non-transplant)

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Shared care protocol – hydroxychloroquine for adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

NHS Medicines Optimisation Opportunities Dashboard 2023-24

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

The RDTC has developed a Northern regions dashboard to highlight the current position of the ICBs across the North of England in relation to these 16 priorities. It will incorporate the metrics that are being developed nationally, but also include metrics which are designed to support medicines optimisation opportunities across the North.

Metrics within this dashboard continue to be developed and updates will be communicated out to stakeholders as they happen. We do not at this time intend to include sub ICB level data.

The dashboard is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

Problematic Polypharmacy:  Prescribing Cascades Evidence Evaluation

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

Problematic polypharmacy is a significant concern with overprescribing and occurs where the prescribing of multiple medicines is either inappropriate or where the intended benefit of the medication is not realised. Prescribing cascades contribute to problematic polypharmacy because they can lead to inappropriate medication use, adverse drug reactions, poor outcomes and increased healthcare resource use that could be avoided.

The publication aims to raise awareness of potential prescribing cascades and to highlight resources, tools, and strategies to help identify, prevent, and resolve inappropriate cascades.

Monthly Horizon Scanning Report – February 2023

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Prescribing Update Newsletter – February 2023

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on RDTC resources to help you make the most of your budget, updates to the cost comparison charts, the voluntary recall of certain FreeStyle Libre 2 sensors, and an E-learning programme on internet safety, suicide, and self-harm. It highlights recent publications from the RDTC including a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing, and a Prescribing Bulletin looking at the budget impact of Metformin immediate release 1g tablets. It also includes another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on some key medicines availability issues and serious shortage protocols

Polypharmacy & Overprescribing: Opioid population health management

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing:

Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of overprescribing and polypharmacy opioid publications, the suggested actions have only been listed in the most relevant theme but may apply across all. We recommend reading all parts of the series sequentially to ensure the breadth of potential actions are known.

This is the third part of the series which focuses on the population health management of patients prescribed opioids, specifically in terms of deprivation level and the impact on sustainability and climate change.

Use the following links to access the first part in the series entitled ‘Opioid patient populations’ and the second in the series entitled ‘Opioid patient demographics’